This analysis revealed that high expression of LOXL2 was strongly correlated with advanced pathological characteristics of glioma, IDH wild type and 1p/19q non-codeletion, suggesting its potential value as a biomarker for malignant progression of glioma. Here, LOXL2 is linked to central nervous system cancer.